GRZAN Bangladesh Medical Device Registration Service

1. Key takeaways

GRZAN provides end-to-end DGDA registration services in Bangladesh for medical device and IVD manufacturers, covering nine stages from classification through to post-market maintenance. The service is structured around the way DGDA actually works: a paper process, a two-step submission, a legalisation chain for the CFS, and a licence-holding arrangement that determines who controls the certificate after approval. Each stage produces a defined deliverable, so the client can see where a file stands without asking for a status update.

• The classification opinion is issued in writing under §4.4 of the DGDA guideline, and covers combination devices and CFS coverage.
• The holding structure is designed so that registration and distribution sit in different entities, with four core terms in the agreement.
• The CFS legalisation chain involves notarisation, foreign ministry and embassy steps, because Bangladesh is not a Hague Convention state and does not accept Apostille.
• Submission is two-step: formula approval first, then final registration with the original CFS and physical original packaging.
• Post-market support covers vigilance reports within 10 working days of knowledge, the PMS system, and recall and change management.

2. Legal basis

Each stage of the service maps onto a requirement in the DGDA framework or onto a step that the framework makes unavoidable in practice. The table sets out the nine stages and what each one delivers, so that the scope of work is defined before a project starts rather than negotiated while it is running.

The sequence is not arbitrary. Stage one determines which requirements apply, because classification drives the evidence set. Stage two determines who will hold the certificate, which has to be settled before documents are addressed to a licence holder. Stage four determines the physical form of the CFS, and stage five cannot be scheduled without knowing how long the legalisation chain will take. Stages six and seven convert an approved file into goods that can lawfully move, and stages eight and nine keep the approval alive. A file that begins at stage three, which is the most common way projects arrive with us, usually has to go back to stage one.

3. Expert insights

Insight one: the two-step submission is the structural feature most often underestimated. Formula approval and final registration are separate steps with separate evidence, and the first is tied to a quarterly committee session. That single fact changes the shape of a project schedule: the date of the committee becomes the anchor, and everything before it is planned backwards. A manufacturer who plans forwards from a document-ready date will miss the session and wait a full quarter. Scheduling backwards from the committee date is the first thing we do on any new file.

Insight two: the CFS legalisation chain is a fixed physical constraint, not an administrative formality. Bangladesh is not a Hague Convention state and does not accept Apostille, so the CFS has to travel through notarisation, the foreign ministry and the embassy in sequence. Each step consumes time and depends on the previous one being completed correctly. Because the chain sits upstream of the submission, a defect discovered at the embassy stage delays the entire project.

Insight three: the division of labour between GRZAN and the local partner is what makes the structure work. Registration in Bangladesh is delivered jointly by the GRZAN registration team and a Bangladeshi licensed partner. GRZAN handles regulatory strategy, document preparation, the cross-border document chain and project control; the local partner holds the DIL and the trade licence, acts as licence holder, makes the physical submission and conducts on-site communication with DGDA. The split follows capability rather than convenience: strategy and documentation can be run from outside the country, while holding a licence and standing in front of an officer cannot.

Insight four: post-market obligations should be scoped at the start, not added after approval. Stage eight is often treated as something to arrange once the certificate is issued, which is too late for two reasons. The first is that vigilance reporting runs on a 10 working day clock measured from the date of knowledge, and that clock does not wait for a contract to be signed. The second is that the PMS system required by the guideline takes time to build and longer to evidence. Wrapping it into the project scope at stage one costs less than constructing it under the pressure of a live event.

Insight five: renewal is a calendar obligation, and the CE certificate is the item that catches companies out. Stage nine exists because a 5-year validity period is long enough to be forgotten and short enough to arrive while a product is still commercially important. Linking the renewal calendar to the CE certificate expiry date means the two are reviewed together, so that a renewal is not started with a supporting certificate that is about to lapse. Setting that linkage up at the beginning is simple; reconstructing it later is not.

4. Practical recommendations

For a project assessment covering timeline and cost, the regulatory team can be contacted directly. At project initiation we provide three documents for internal decision-making: a classification opinion, a project schedule, and a five-year total cost of ownership. The three are issued together so that classification, schedule and cost can be compared as one decision.

• Start with a written classification opinion under §4.4, and confirm CFS coverage for combination devices before drafting the technical file.
• Settle the holding structure and the four core agreement terms before documents are addressed to any licence holder.
• Schedule the submission backwards from the quarterly committee session, and treat the session date as fixed.
• Begin the CFS legalisation chain early, and check wording and format before the first notarisation rather than at the embassy stage.
• Prepare the method validation report and the ISO/IEC 17025 report as part of stage six, so that a sample request does not stall the file.
• Confirm MRP approval before release for sale, and coordinate the per-batch NOC for each import.
• Build the vigilance and PMS arrangements during the project, so that the 10 working day clock is operable on the day the certificate is issued.

5. Verification checklist

• □ A written classification opinion has been issued under §4.4, including CFS coverage for combination devices
• □ The holding structure is agreed, with the four core terms written into the agreement
• □ The English technical file, compliance matrix, master formula and label specimens are complete
• □ The CFS legalisation route is confirmed as notarisation, foreign ministry and embassy, with no Apostille
• □ Formula approval has been scheduled against the quarterly committee session
• □ Sample NOC, method validation and ISO/IEC 17025 reports are prepared for stage six
• □ MRP approval and per-batch NOC arrangements are in place before release for sale
• □ The 5-year renewal calendar is linked to CE certificate expiry dates

Regulatory information verified as at 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com